Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan may spare bladder cancer patients from surgery

NCT ID NCT04321707

Diagnosis Sponsor: Jørgen Bjerggaard Jensen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special type of PET/MR scan (using radioactive water) can accurately tell if bladder cancer has been completely eliminated by chemotherapy. 13 patients with muscle-invasive bladder cancer were scanned before and after chemotherapy, and the results were compared to the actual tissue removed during surgery. The goal is to find a non-invasive way to identify patients who are cancer-free and might safely avoid bladder removal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
15O-H2O PET/MR scan
What this could lead to
If successful, this scan could help identify bladder cancer patients who are cancer-free after chemotherapy, allowing them to keep their bladder instead of having it removed.
What could go wrong
This is a very small, early study with only 13 participants. The scan may not be accurate enough to replace standard surgery, and more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

May 2020

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of MIBC stage cT2-4a. * Preoperative PET/CT of thorax, abdomen, and pelvis with no suspicion of organ metastases or lymph node metastasis outside the surgical field. * ≥18 years of age at the time of signing the Informed Consent Form. Renal function of eGFR \> 60 ml/min/1,73 m2. * Physically fit for NAC. * Clinical decision with patient accept of NAC before cystectomy. * Mentally healthy. Signed Informed Consent Form. Exclusion Criteria: \- Unfit for MRI: * Claustrophobia. * Problems with seating arrangements (e.g. pain or involuntary movement). * Maximal shoulder width larger than 55 cm. * Circumference larger than 160 cm. * Weight above 250 kg. * Metallic implants or other metallic foreign bodies. * Pacemaker, ICD, or pace electrodes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer

Contacts and locations

Locations

  • Department of Urology, Aarhus University Hopsital

    Aarhus, 8000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.